Cai et al. found that dapagliflozin (sodium-glucose cotransporter 2 inhibitor; SGLT2i) suppressed the HIF-1α-mediated metabolic switch from lipid oxidation to glycolysis in kidney tubule cells of diabetic mice and significantly improved diabetes-induced tubulointerstitial damage, such as macrophage infiltration and fibrosis [9]. This evidence concerns the gene SLC5A2 and diabetes mellitus.